SCHEMBL885836

SCHEMBL885836

COCCCOc1ccccc1-n1c(-c2ccccc2)c(C(=O)O)[nH]c1=O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
REN P00797 2/20 0.42
KDM4E B2RXH2 4/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.40
MCL1 Q07820 6/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALB P02768 1/20 0.36
BCL2 P10415 1/20 0.36
NTRK1 P04629 2/20 0.36
NTRK3 Q16288 2/20 0.36
NTRK2 Q16620 2/20 0.36
PPARG P37231 2/20 0.36
AVPR2 P30518 1/20 0.36
AVPR1A P37288 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL885838 0.94 NTRK1 (0.40) RENKDM4EL3MBTL1GAAMCL1
SCHEMBL885801 0.89 MAPT (0.40) RENKDM4EL3MBTL1GAAMAPT
SCHEMBL885725 0.86 REN (0.47) RENKDM4EL3MBTL1GAAMAPT
SCHEMBL2062794 0.85 REN (0.56) RENKDM4EMAPTMEN1KMT2A
SCHEMBL885791 0.83 LMNA (0.43) L3MBTL1GAAMAPTSMN1; SMN2NTRK1
SCHEMBL8164725 0.81 REN (0.43) RENMAPTMEN1KMT2A
SCHEMBL885499 0.81 REN (0.45) RENKDM4EGAAMCL1MEN1
SCHEMBL886038 0.81 REN (0.42) RENL3MBTL1GAAMAPTMEN1
SCHEMBL2062523 0.80 REN (0.51) RENKDM4EMAPTMEN1KMT2A
SCHEMBL8171275 0.76 MEN1 (0.41) RENMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO claimed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT REN 1/4885KDM4E 2733/4885L3MBTL1 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.